---
figid: PMC4618268__nihms-703863-f0001
figtitle: 'Everolimus Combined With Gefitinib in Patients with Metastatic Castration-Resistant
  Prostate Cancer: Phase I/II Results and Signaling Pathway Implications'
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC4618268
filename: nihms-703863-f0001.jpg
figlink: /pmc/articles/PMC4618268/figure/F1/
number: F1
caption: 'RTK: receptor tyrosine kinase; EGFR: epidermal growth factor receptor; AR:
  androgen receptor. Activation of AKT and mTOR has been shown to feedback inhibit
  the activation, expression and signaling of a variety of RTKs, including members
  of the EGFR family, IGF1R, HER2/3 and others. Rapamycin-like drugs can relieve this
  feedback and activate RTKs, thereby attenuating the anti-tumor effect of these drugs.
  Inhibition of PI3K can activate AR through relief of negative feedback on RTK. Conversely,
  inhibition of AR activates AKT by reducing levels of the AKT phosphatase PHLPP.'
papertitle: 'Everolimus Combined With Gefitinib in Patients with Metastatic Castration-Resistant
  Prostate Cancer: Phase I/II Results and Signaling Pathway Implications.'
reftext: Dana E. Rathkopf, et al. Cancer. ;121(21):3853-3861.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9248849
figid_alias: PMC4618268__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC4618268__F1
ndex: 4755b2df-dea5-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4618268__nihms-703863-f0001.html
  '@type': Dataset
  description: 'RTK: receptor tyrosine kinase; EGFR: epidermal growth factor receptor;
    AR: androgen receptor. Activation of AKT and mTOR has been shown to feedback inhibit
    the activation, expression and signaling of a variety of RTKs, including members
    of the EGFR family, IGF1R, HER2/3 and others. Rapamycin-like drugs can relieve
    this feedback and activate RTKs, thereby attenuating the anti-tumor effect of
    these drugs. Inhibition of PI3K can activate AR through relief of negative feedback
    on RTK. Conversely, inhibition of AR activates AKT by reducing levels of the AKT
    phosphatase PHLPP.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pik3r1
  - Erbb3
  - Erbb2
  - Igf1r
  - Egfr
  - Ar
  - Akt1
  - Ephb2
  - Mapk1
  - Phlpp1
  - Mt2
  - Mtnr1b
  - Fkbp5
  - Rps6kb1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ERBB3
  - ERBB2
  - IGF1R
  - EGFR
  - AR
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - PHLPP1
  - MTOR
  - RPTOR
  - MAPKAP1
  - RICTOR
  - MLST8
  - MT2A
  - MTNR1B
  - TMPRSS6
  - FKBP5
  - RPS6KB1
---
